FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 ...Middle East

Phase 1/2 first-in-human clinical study planned this year SHANGHAI and SAN DIEGO, May 22, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology...

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 )

Also on site :

• Diddy Trial Recap: Kid Cudi Testifies About Home Break-In and Porsche Molotov Cocktail Explosion
• Matthew Goode Explains Absence From ‘Downton Abbey 3’: “Maybe It’s A Good Thing”
• Columbia student activist seized by ICE agents holds month-old son for first time after 10 weeks of detention